Prostate Cancer Clinical Trials in Detroit

Showing 241-260 of 408 trials

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02711956

This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.

Metastatic Castration-Resistant Prostate Cancer

Zenith Epigenetics75 participantsStarted Dec 2016

Los Angeles, California, United States • San Francisco, California, United States • Detroit, Michigan, United States +5 more locations

COMPLETEDPhase 1< 1 mile

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

NCT02655822

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Renal Cell CancerMetastatic Castration Resistant Prostate Cancer

Corvus Pharmaceuticals, Inc.502 participantsStarted Jan 2016

Tucson, Arizona, United States • San Francisco, California, United States • Stanford, California, United States +17 more locations

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Prostate Cancer Trials in Other Cities

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Safety Study of MGA271 in Refractory Cancer

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Other Conditions in Detroit